OBJECTIVE:To probe into the efficacy and safety of febuxostat in treatment of gout. METHODS:126 patients with primary gout admitted into the First People's Hospital of Yichang from Aug. 2015 to Jun. 2017 were selected and divided into observation group and control group via random number table, with 63 cases in each. The observation group was treated with febuxostat, while the control group was given allopurinol. The blood uric acid levels, compliance rate of blood uric acid and incidences of adverse drug reactions between two groups before and after treatment were observed. RESULTS:After treatment, the blood uric acid levels of observation group and control group were respectively (318.91±48.42) μmol/L and (342.56±67.63) μmol/L, both were significantly lower than those of before treatment, and that of the observation group was significantly lower than the control group, with statistically significant differences (P＜0.05). The compliance rate of blood uric acid of observation group was 82.5％ (52/63), which was significantly higher than that of the control group (68.3％, 43/63), with statistically significant difference (P＜0.05). During treatment, the incidence of adverse drug reactions of observation group was 4.8％ (3/63), which was significantly lower than that of the control group (14.3％, 9/63), with statistically significant difference (P＜0.05). CONCLUSIONS:Febuxostat can effectively reduce the blood uric acid level for patients with gout, with high safety.%目的:探讨非布司他治疗痛风的临床疗效及安全性.方法:选取2015年8月至2017年6月宜昌市第一人民医院收治的原发性痛风患者126例,以随机数字表法分为观察组和对照组,每组63例.观察组患者给予非布司他治疗,对照组患者给予别嘌呤醇治疗.观察两组患者治疗前后的血尿酸水平、血尿酸达标情况及不良反应发生情况.结果:治疗后,观察组、对照组患者血尿酸水平分别为(318.91±48.42)、(342.56±67.63)μmol/L,均较治疗前明显降低,且观察组患者明显低于对照组,差异均有统计学意义(P＜0.05).观察组患者的血尿酸达标率为82.5％(52/63),明显高于对照组的68.3％(43/63),差异有统计学意义(P＜0.05).治疗期间,观察组患者的不良反应发生率为4.8％(3/63),明显低于对照组的14.3％(9/63),差异有统计学意义(P＜0.05).结论:非布司他可有效降低痛风患者的血尿酸水平,且安全性较高.
展开▼
